Aquestive Therapeutics (AQST) reported $11.87 million in income for the quarter ended December 2024, representing a year-over-year decline of 10.2%. EPS of -$0.19 for a similar interval compares to -$0.12 a yr in the past.
The reported income represents a shock of -12.11% over the Zacks Consensus Estimate of $13.5 million. With the consensus EPS estimate being -$0.14, the EPS shock was -35.71%.
Whereas traders intently watch year-over-year adjustments in headline numbers — income and earnings — and the way they examine to Wall Road expectations to find out their subsequent plan of action, some key metrics all the time present a greater perception into an organization’s underlying efficiency.
As these metrics affect top- and bottom-line efficiency, evaluating them to the year-ago numbers and what analysts estimated helps traders undertaking a inventory’s value efficiency extra precisely.
Right here is how Aquestive Therapeutics carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Road analysts:
- Revenues- Manufacture and provide income: $10.66 million in comparison with the $11.38 million common estimate primarily based on 4 analysts. The reported quantity represents a change of -3% yr over yr.
- Revenues- License and royalty income: $0.83 million versus the four-analyst common estimate of $1.86 million. The reported quantity represents a year-over-year change of -55.6%.
- Revenues- Co-development and analysis charges: $0.27 million in comparison with the $0.43 million common estimate primarily based on three analysts. The reported quantity represents a change of -18.2% yr over yr.
- Income – Proprietary product gross sales, web: $0.10 million in comparison with the $0.20 million common estimate primarily based on two analysts.
View all Key Company Metrics for Aquestive Therapeutics here>>>
Shares of Aquestive Therapeutics have returned -11.1% over the previous month versus the Zacks S&P 500 composite’s -4.1% change. The inventory at present has a Zacks Rank #3 (Maintain), indicating that it might carry out according to the broader market within the close to time period.
Zacks Names #1 Semiconductor Inventory
It is just one/9,000th the dimensions of NVIDIA which skyrocketed greater than +800% since we really useful it. NVIDIA continues to be sturdy, however our new high chip inventory has way more room to growth.
With sturdy earnings development and an increasing buyer base, it is positioned to feed the rampant demand for Synthetic Intelligence, Machine Studying, and Web of Issues. International semiconductor manufacturing is projected to blow up from $452 billion in 2021 to $803 billion by 2028.
See This Stock Now for Free >>
Aquestive Therapeutics, Inc. (AQST) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
